前往化源商城

3233-32-7 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1B1
External ID: CHEMBL3039488
Protocol: N/A
Comment: Journal: Mol Pharmacol
Year: 2013
Volume: 83
Issue: 6
First Page: 1257
Last Page: 1267
DOI: 10.1124/mol.112.084152

Target ChEMBL ID: CHEMBL1697668
ChEMBL Target Name: Solute carrier organic anion transporter family member 1B1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=65.85%
Inhibition=63.37%
Inhibition=75.25%
Inhibition=97.38%
Inhibition=105.26%
Inhibition=97.94%
Inhibition=105.32%
Inhibition=99.4%
Inhibition=101.01%
Inhibition=86.27%
Inhibition=80.06%
Inhibition=89.01%
Inhibition=120.91%
Inhibition=102.46%
Inhibition=101.26%
Inhibition=90.74%
Inhibition=113.76%
Inhibition=82.92%
Inhibition=126.2%
Inhibition=116.63%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:24565 靶标:N/A
External ID: ERK5 transcriptional activity-HTS
Protocol: Stable cells plated on a 384-well plate (2500 cells/well) were treated with test compounds at the concentration of 5 muM for 18 hrs. The level of luciferase activity was assayed using a
Luciferase kit (Promega corporation, Madison, WI) and a series of positive and negative control compounds were used as references.
Comment:
Luciferase activity (AU)
104
108
64
28
100
152
176
52
124
44
60
60
32
96
60
144
28
64
84
44
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:11908 靶标:N/A
External ID: RMI-FANCM-MM2
Protocol: FP HTS. Screening took place at the University of Wisconsin Small Molecule Screening and Synthesis Facility. A master mix of RMI core complex and F-MM2 (30 microL per well) was plated in black 384 shallow well plates (ThermoFisher, Waltham, MA), using a BioTek "MicroFlo Select" reagent dispenser. Compounds were added using a Beckman FX liquid handler; 0.33 microL of 10 mM stock was added for a final compound concentration of 33 microM. MM2 and cMM2 were each added to 4 wells of master mix per plate to a final concentration of 10 muM to serve as controls. Following compound addition, plates were covered, centrifuged briefly, and incubated for 20 minutes at room temperature. FP measurements were taking using a Tecan "Safire 2" microplate reader. Instrument settings were as follows: top read, EX 470, EM 525/20, G-factor 0.89947. A suitable gain was calculated from the first plate of each day. Z' scores for were calculated for each plate; plates with Z' scores <0.5 were rerun prior to analysis.
Comment:
Concentration uMData readout
3355
3363
3365
3363
3361
3362
3361
3358
3371
3361
3364
3383
33158
3384
33104
3360
3362
3359
3358
3359
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: MCF7_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, MCF7 is panel number 5, cell number 1. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
2106OS49SM1.0E-551Breast CancerMCF7BRE88.231101
2106OS49SM1.0E-551Breast CancerMCF7BRE87.1119101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.4371101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.7113101
2106OS49SM1.0E-551Breast CancerMCF7BRE97.2463101
2106OS49SM1.0E-551Breast CancerMCF7BRE90.0129101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.7031101
2106OS49SM1.0E-551Breast CancerMCF7BRE30.8539101
2106OS49SM1.0E-551Breast CancerMCF7BRE14.2896101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.8526101
2106OS49SM1.0E-551Breast CancerMCF7BRE83.1036101
2106OS49SM1.0E-551Breast CancerMCF7BRE84.2194101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.3237101
2106OS49SM1.0E-551Breast CancerMCF7BRE85.6034101
2106OS49SM1.0E-551Breast CancerMCF7BRE89.6643101
2106OS52SM1.0E-551Breast CancerMCF7BRE91.2503101
2106OS52SM1.0E-551Breast CancerMCF7BRE94.8714101
2106OS52SM1.0E-551Breast CancerMCF7BRE93.7372101
2106OS52SM1.0E-551Breast CancerMCF7BRE112.6132101
2106OS52SM1.0E-551Breast CancerMCF7BRE73.375101
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:DTP/NCI 靶标:N/A
External ID: IGROV1_OneDose
Protocol: NCI-60 Human Tumor Cell Lines Screen was performed using the standard one-dose NCI protocol, which is described in more detail at https://dtp.cancer.gov/discovery_development/nci-60/default.htm.

Compounds with GIPRCNT values below 10 were considered active. Activity score was based on GIPRCNT using the following formula:
max(-GIPRCNT/2 + 50, 0)
Score is 0 for GIPRCNT values of 100 or above, 50 for GIPRCNT values of 0, and 100 for GIPRCNT values of -100.
Comment: These data are a subset of the data from the NCI human tumor cell line screen. Compounds are identified by the NCI National Service Center (NSC) number, which is contained in the
PUBCHEM_EXT_DATASOURCE_REGID field. In the NCI cell line identification system, IGROV1 is panel number 6, cell number 10. PANELCODE or PANELNAME identify the NCI-60 cell panel. PANELNBR does NOT identify the NCI-60 panel.

EXPID is the NCI internal tracking number for the experiment identifier, and PREFIX = 'S' for the NSCs submitted through the NCI Chemical Agents repository.

Substance concentration unit is indicated in the data table, using the following abbreviations: M = molar (M), u = micrograms/milliliter (microg/mL), V = volumetric fraction.

M_GIPRCNT represents the mean growth percent for that experiment, and N_GIPRCNT indicates the number of values for that NSC within an experiment, while STDEV_GIPRCNT is the standard deviation. Most NSCs are tested once per experiment, resulting in EXP_COUNT = 1.
EXPIDPREFIXCONCENTRATION_UNITCONCENTRATIONPANELNBRCELLNBRPANELNAMECELLNAMEPANELCODEM_GIPRCNTN_GIPRCNTSTDDEV_GIPRCNTEXP_COUNT
0809OS51SM1.0E-5610Ovarian CancerIGROV1OVA89.6274101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA94.0185101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA77.1805101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA76.1686101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA82.5618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA88.7561101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA83.5845101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA92.7497101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA70.9555101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA58.7306101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.6041101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA90.3839101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA110.2345101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA97.6538101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA93.7697101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA56.4618101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA80.8893101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA79.078101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA-20.3008101
0810OS71SM1.0E-5610Ovarian CancerIGROV1OVA72.0949101
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23209 靶标:N/A
External ID: UIHTS20180925
Protocol: Assay overview:
The purpose of this assay is to identify test compounds that differentially kill either epithelial cells or mesenchymal cells, critical components of EMT. The PC-3E+ and TEM4-18 cell lines, characterized as epithelial cells and mesenchymal cells respectively, were established in Henry Lab (Ref 1). For potential discriminative modulators of EMT, the two cells lines were labeled with GFP and mCherry respectively, and co-cultured together to eliminate those hits that non-discriminatingly kill both epithelial cells and mesenchymal cells by cytotoxicity irrelevant to the EMT properties.
Protocol for the EMT project:
The primary screening data were generated as described in HTS assay protocol table (Ref 2).

Table 1: HTS assay protocol table
Step Parameter Value Description
1. Plate cells 200 uL By MultiFlo. PC3E GFP 2,000 cells/ well and TEM418 mCherry 2,000 cells/well (1:1). Overnight incubation
2. Remove media Flip the plate
3. Add fresh media 150 uL By MultiFlo
4. Controls 200 uL C01-H01, C12 -H12, Hygromycin dose response from H to C were positive control. Wells A01, B01, A12 and B12 were negative control
5. Library 50 uL MSSP library 1 uM final from middle plate in full media
6. Incubation 72 hrs 37 C and 5% CO2
7. Assay readout GFP and mCherry channel imaging Perkin Elmer Operetta high content imaging system, with Harmony image analysis software.
8. Image analysis Green cells and Read cells counting Normalized to the average cell number of well B1 and B12 (no inhibition of cell viability) controls on each plate to get relative cell viability for each well.
9. Hit selection 11 hits The hit criteria for preferential cell killing are compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal
0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing OR Greencells_Normalized is
lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent
by itself for Green cell killing.

The primary screening data (imaging data) were translated into Green or Red cell numbers in each well in the data file.
Comment: Preferential killing compounds are considered as active hits (score of 100) when meeting one of two groups of criteria:

1. Compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal 0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing.

OR

2. Greencells_Normalized is lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent by itself for Green cell killing.
No. of GreenCellsNo. of RedCellsGreenCells_NormalizedRedCells_NormalizedRedCells/GreenCells_Normalized
178911800.881.081.22
196110810.970.991.02
187612910.931.181.27
224410941.1110.9
227512101.121.110.98
199513980.981.281.3
212312931.051.181.13
228112271.131.121
196410900.9711.03
211012951.041.181.14
234213611.161.241.08
201413160.991.21.21
2021127011.161.16
216012871.071.181.1
2022119711.091.1
179810820.890.991.11
193811991.081.060.98
200012601.121.110.99
197112011.11.060.96
210011301.1710.85
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23265 靶标:IucA Synthetase from hypervirulent Klebsiella pneumoniae hvKP1
External ID: IucA Pilot Assay Spectrum Library
Protocol: A solution containing 55.6 mM HEPES pH 7.5, 0.11% Tween 20, 16.7 mM MgCl2, 55.6 mM hydroxylamine, 55.6 microM ATP, 55.6 microM citrate, and 0.28 U/mL IPP was dispensed (45 microL) into clear polystyrene microplates (Corning, Inc.) using a BioTek MicroFlo dispenser.

Next, 40 nL of test compounds (10 mM in DMSO, 8 microM final concentration) were transferred from deep-well blocks to the reaction solution using a stainless-steel pin tool operated by a robotic workstation (JANUS, PerkinElmer, Waltham, MA). The IucA-catalyzed reaction was initiated by adding 5 microL of 3 microM IucA in 25 mM HEPES, 75 mM NaCl, and 0.1 mM TCEP at pH 7.5.

The reactions were allowed to proceed for 30 min at room temperature before being quenched by dispensing (microFill, BioTek) 13 microL of MG developing solution, containing 1.0 mg/mL MG oxalate, 1.5% (w/v) ammonium molybdate, 0.15% (v/v) Tween 20, and 4.7 N sulfuric acid. After allowing the assay color to develop/stabilize for 30 min, the absorbance at 620 nm was measured (EnVision 2103 Multilabel Microplate Reader, PerkinElmer).

Average positive controls from 24 wells with no test compound and average negative controls from 8 wells with no enzyme were calculated. Dynamic range was calculated by difference between Avg Pos Control and Avg Neg Control. Percent inhibition was calculated by the ratio of (Avg. Pos. Ctrl - Sample OD) to Dynamic Range.
Comment: Protein Target is
IucA

EMB09144
574 aa
G057_19877
Klebsiella pneumoniae hvKP1

Active compounds were defined by <80% activity at 8 microM screening concentration.
OD%Activity384ID
1.054109.5793076877485A04
1.048108.5123881216295A05
1.085115.0917254460325A06
1.154127.3613004564045A07
1.12121.3154229150615A08
1.115120.4263232766295A09
1.126122.3823424811815A11
1.154127.3613004564045A12
1.138124.5161816134195A13
1.17130.2064192993895A14
1.155127.5391203840915A16
1.128122.7379823365545A17
1.156127.7169403117785A18
1.053109.4014877600625A19
1.052109.2236678323755A20
1.067111.8909667476735A21
1.032105.6672692786445A22
1.062111.0018671092415B03
1.091116.1586450121515B06
1.108119.1815837828235B08
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1B3
External ID: CHEMBL3039491
Protocol: N/A
Comment: Journal: Mol Pharmacol
Year: 2013
Volume: 83
Issue: 6
First Page: 1257
Last Page: 1267
DOI: 10.1124/mol.112.084152

Target ChEMBL ID: CHEMBL1743121
ChEMBL Target Name: Solute carrier organic anion transporter family member 1B3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=89.51%
Inhibition=81.71%
Inhibition=65.47%
Inhibition=50.32%
Inhibition=112.43%
Inhibition=99.94%
Inhibition=101.75%
Inhibition=98.72%
Inhibition=104.08%
Inhibition=114.2%
Inhibition=97.5%
Inhibition=120.61%
Inhibition=45.56%
Inhibition=105.72%
Inhibition=107.28%
Inhibition=93.09%
Inhibition=84.51%
Inhibition=155.79%Outside typical range
Inhibition=97.26%
Inhibition=72.91%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:11924 靶标:N/A
External ID: CGM data for Cell Systems paper Dec 2015
Protocol: Yeast strains and Media:
All S. cerevisiae deletion strains were obtained from the Euroscarf deletion collection. The wild type parental strain for this collection is BY 4741 MATa his31 leu20 met150 ura30. An isogenic pdr1pdr3 strain (MT2481) was created using PDR1::nat and PDR::URA3 deletion cassettes. All strains were grown and screened in synthetic complete (SC) medium with 2% glucose.

Handling:
Strains were seeded at 50,000 cells per well in a volume of 100 L in 96 well plates followed by addition of 2 L of 1 mM compound stock for final concentration of 20 M. Screens were conducted in technical duplicate using a Biomek FX liquid handling workstation with an integrated stacker carousel. DMSO solvent only controls and 10 uM cycloheximide positive controls were seeded in columns 1 and 12 of each assay plate. Plates were incubated at 30 C without shaking for approximately 18 h or until culture saturation was achieved for the solvent controls. Cultures were resuspended by shaking on the robotic platform prior to reading OD600 values on either Tecan M1000 or Tecan Sunrise plate readers.

Analysis procedure:
All data was subjected to the following workflow:
1. Consistent spatial effects on growth across plates were corrected by Lowess regression using an empirically estimated sliding window of 1/3 and normalized based on plate median.
2. If more than 30% of compounds were active within a plate, data was normalized to DMSO controls.
3. Median normalization was applied to all plates and experiments.
4. Z-factors for growth inhibition were calculated using the median and the interquartile range (IQR) by fitting a normal distribution with N(1,IQR) to the experimental data. In addition, we calculated the Z-factor, percent inhibition and normalized OD values for manual validation.
5. Data points with high variation between replicates (> 3 MAD) were removed as inconsistent outliers.

BioAssay submission file header:

Pubchem_ext_datasource_regid: compound identifier used in on chemgrid.org/cgm
Orf yeast gene deletion (open reading frame)
Sym# yeast gene deletion gene symbol
Raw OD read 1 first replicate
Raw OD read 2 second replicate
Normalized OD average normalized read based on workflow described above
Z_score Z-Score calculated based on kernel density distribution from normalized average reads per screen
P_value p-value calculated based on kernel density distribution calculated from average reads per screen
Non replicate test for non-replicates between first and second replicate
Pubchem_activity_outcome pubchem activity outcome
Cryptagen if compound identifier fulfilled cryptagen rule of activity in at least 4 and not more than 2/3rds of screens per library
Bioactivity sensitive if compound decreases fitness or resistant if compound increases fitness compared to negative control
Comment:
orfsymraw OD read 1raw OD read 2normalized OD averagez_scorep_valuenon replicatecryptagenbioactivity
YMR263WSAP300.81090.82411.007920.6765250.25126700
YMR263WSAP300.70740.70450.999472-0.02700660.43853300
YMR263WSAP300.71320.82811.017960.6225070.27234601
YMR263WSAP300.80970.70871.008750.7614850.22641600
YMR263WSAP300.69810.82591.01050.3744620.35427900
YMR263WSAP300.80850.70631.005020.4370360.33193100
YMR263WSAP300.65350.68970.990762-0.3283280.37139400
YMR263WSAP300.81330.69411.007170.5988890.29095200
YMR263WSAP300.68670.80190.976773-0.8247460.20524700
YMR263WSAP300.78360.68620.991018-0.7716340.22038900
YMR263WSAP300.59950.61390.893377-3.803870.00037803201
YMR263WSAP300.62710.80940.962532-1.306830.10774100
YMR263WSAP300.68780.69570.980366-0.6848680.24993400
YMR263WSAP300.68680.69620.978746-0.7416890.23281100
YMR263WSAP300.65410.64840.937529-2.232410.02007301
YMR263WSAP300.81210.82591.009720.8309410.20515300
YMR263WSAP300.68160.69681.002080.06816690.4595700
YMR263WSAP300.70580.79830.990309-0.3607950.36655800
YMR263WSAP300.78730.80340.980792-1.660550.049953200
YMR263WSAP300.69170.70120.997639-0.08757040.46520801
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:11827 靶标:Phosphogluconate dehydrogenase
External ID: 6PGD_Inhibitor_Screening_2015_09
Protocol: The screening assay was performed in a 96-well reading plate, the reaction of each well is 200ul which contains:

50 mM Tris (pH 8.1),
0.2 mM 6-phosphogluconate,
1 mM MgCl2,
0.1 mM NADP+,
0.5 ug recombinant human 6PGD protein,
and 10 uM compound candidate.

The increase in absorbance at 341 nm was measured using a SpectraMax Plus spectrophotometer (Molecular Devices)
Comment: Please note:
This is primary screening data, and for further confirmation, compound that shows equal or over 20% inhibition of 6PGD enzyme activity in this assay is considered as a potential inhibitor.
Percentage of inhibitionBIOACTIVITY_PHENOTYPE
-7.36402
-2.25941
0.502092
-6.10879
1.841
-10.795
-25.3556
-10.6276
-7.61506
10.0833
-2.91667
2.66667
-18.75
-18.3333
-19.4167
-24.5
3.16667
13.5
5.47112
10.9422